Search results for "Vaccination"


 
Results 121 - 130 of about 516 for "Vaccination".
Sort by: Relevance | Newest | Oldest

Treatment for high-risk COVID-19 patients, vaccine news, research on health messaging

An industry-funded study found benefit with bamlanivimab plus etesevimab for high-risk ambulatory COVID-19 patients, the FDA noted a possible increased risk for Guillain-Barré syndrome with the Johnson & Johnson (Janssen) vaccine, and two studies looked at COVID-19 messaging for minority populations.
https://immattersacp.org/weekly/archives/2021/07/20/1.htm
20 Jul 2021

New vaccine authorization and data, NIH on antibody treatment and ‘long COVID’

The Johnson & Johnson COVID-19 vaccine got an emergency use authorization, and an Israeli study provided more data on the Pfizer vaccine. The NIH recommended an antibody combo for outpatients and named long-term symptoms as post-acute sequelae of SARS-CoV-2 (PASC).
https://immattersacp.org/weekly/archives/2021/03/02/1.htm
2 Mar 2021

Postexposure prophylaxis drug, vaccine complications, and anticoagulation in COVID-19

A monoclonal antibody combination was effective for postexposure prophylaxis and received emergency use authorization. A study investigated postvaccine myocarditis and pericarditis, and effects of full-dose anticoagulation differed by whether patients were critically ill.
https://immattersacp.org/weekly/archives/2021/08/10/1.htm
10 Aug 2021

Studies assess responses, reactions to vaccines; long-term effects of COVID-19 infection

Recent COVID-19 vaccine studies showed good response in pregnant women, as well as possible localized rashes from the Moderna vaccine. Analyses of ICU patients and those treated at a post-COVID-19 clinic highlighted the long-term effects of the virus, and a study found that dialysis patients maintained antibodies six months after COVID-19 infection.
https://immattersacp.org/weekly/archives/2021/05/18/1.htm
18 May 2021

Clot concerns with adenovirus COVID-19 vaccines, antibody treatment recommendations and data

Based on reports of cerebral venous sinus thrombosis with the Johnson & Johnson (Janssen) COVID-19 vaccine, federal officials recommended a pause in its use, which will be reconsidered on April 23. The NIH updated its recommendations on monoclonal antibody treatments for outpatients.
https://immattersacp.org/weekly/archives/2021/04/20/1.htm
20 Apr 2021

Latest COVID-19 research details local vaccine reactions, ineffective outpatient treatments

A case series described delayed skin reactions to vaccination, and randomized trials indicated that ivermectin, azithromycin, and convalescent plasma didn't help mildly ill patients. Several studies focused on the increase in alcohol use during the pandemic.
https://immattersacp.org/weekly/archives/2021/03/09/1.htm
9 Mar 2021

During National Immunization Awareness Month, ACP urges internists to discuss vaccinations with their patients

ACP advises adults to get an annual flu vaccine and to use that opportunity to discuss with their internist other vaccinations they might need, including Tdap, pneumococcal, human papillomavirus, hepatitis B, and herpes zoster.
https://immattersacp.org/weekly/archives/2018/07/31/6.htm
31 Jul 2018

Distribution plans, data on vaccines; NIH cautious on latest antibody treatment

The Advisory Committee on Immunization Practices chose clinicians and long-term care residents for priority vaccination, while ACP offered additional input on the topic. The NIH said that casirivimab plus imdevimab should not be standard of care, and the CDC offered recommendations on shortening quarantine.
https://immattersacp.org/weekly/archives/2020/12/08/1.htm
8 Dec 2020

CDC recommends COVID-19 booster; ACP updates practice points for outpatient treatment

Everyone ages 6 months and older should get an updated COVID-19 vaccine to protect against a potentially serious outbreak this fall and winter, the CDC said last week.
https://immattersacp.org/weekly/archives/2023/09/19/1.htm
19 Sep 2023

Latest on COVID-19 and bamlanivimab, vaccines, long-term effects

Bamlanivimab reduced viral load in mild to moderate cases when combined with etesevimab, new vaccine recommendations, research, and educational resources were released, and two studies provided longer-term data on patients who had COVID-19.
https://immattersacp.org/weekly/archives/2021/01/26/1.htm
26 Jan 2021

Result Page: Prev   8   9   10   11   12   13   14   15   16   17   Next